葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GSK 葛兰素史克

休市中 04-26 16:00:00 EDT

41.11

+0.20

+0.49%

盘后41.11

+0.000.00%

19:49 EDT

最高41.31	最低40.87	成交量273.05万
今开40.95	昨收40.91	日振幅1.08%
总市值839.89亿	流通市值809.66亿	总股本20.43亿
成交额1.12亿	换手率0.14%	流通股本19.69亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"GSK","market":"US","secType":"STK","nameCN":"葛兰素史克","latestPrice":41.11,"timestamp":1714161600000,"preClose":40.91,"halted":0,"volume":2730464,"hourTrading":{"tag":"盘后","latestPrice":41.11,"preClose":41.11,"latestTime":"19:49 EDT","volume":185380,"amount":7620970.52,"timestamp":1714175353450},"delay":0,"floatShares":1969491234,"shares":2043031374,"eps":3.054466,"marketStatus":"休市中","marketStatusCode":7,"change":0.2,"latestTime":"04-26 16:00:00 EDT","open":40.95,"high":41.3125,"low":40.87,"amount":112374200.93222399,"amplitude":0.010816,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.054466,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1714377600000},"adr":1,"listingDate":977893200000,"adjPreClose":40.91,"adrRate":2,"dividendRate":0.035237,"preHourTrading":{"tag":"盘前","latestPrice":40.94,"preClose":40.91,"latestTime":"09:29 EDT","volume":4702,"amount":192514.47500799998,"timestamp":1714138199999},"postHourTrading":{"tag":"盘后","latestPrice":41.11,"preClose":41.11,"latestTime":"19:49 EDT","volume":185380,"amount":7620970.52,"timestamp":1714175353450},"volumeRatio":1.0492703314671816},"requestUrl":"/m/hq/s/GSK","defaultTab":"news","newsList":[{"id":"2430323586","title":"BUZZ-辉瑞、BioNTech 因葛兰素史克起诉 COVID-19 疫苗技术而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2430323586","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430323586?lang=zh_cn&edition=full","pubTime":"2024-04-25 23:50","pubTimestamp":1714060208,"startTime":"0","endTime":"0","summary":"    4月25日 - ** 疫苗生产商辉瑞  和BioNTech  的股价下跌2%至3%。** 制药商葛兰素史克  起诉  BNTX和PFE，指控它们侵犯了其与信使核糖核酸 技术有关的专利，该技术应用于这两家公司的大片COVID-19疫苗中。** 葛兰素史克称，PFE 和 BNTX 的 Comirnaty 疫苗侵犯了其在 mRNA 疫苗创新方面的专利权，这些创新是在 COVID-19 大流行爆发 \"十多年前 \"开发的。** 葛兰素史克还要求特拉华州联邦法院向这两家公司支付数额不详的赔偿金，其中包括持续的专利许可费。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430428593","title":"葛兰素史克就 Covid-19 疫苗技术起诉辉瑞和 BioNTech","url":"https://stock-news.laohu8.com/highlight/detail?id=2430428593","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430428593?lang=zh_cn&edition=full","pubTime":"2024-04-25 21:35","pubTimestamp":1714052123,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 )) Blake Brittain    路透社4月25日 - 葛兰素史克公司  周四在特拉华州联邦法院起诉辉瑞  和BioNTech  ，指控它们侵犯了葛兰素史克公司与信使RNA(mRNA) 技术有关的专利权，这些技术应用于这两家公司的大片COVID-19疫苗中。葛兰素史克在诉讼中说，辉瑞和 BioNTech 的 Comirnaty 疫苗侵犯了该公司在 mRNA 疫苗创新方面的专利权，而这些创新是在 COVID-19 大流行爆发 \"十多年前 \"开发的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430400804","title":"葛兰素史克公布最新研究结果：重组带状疱疹疫苗欣安立适为50岁及以上人群提供保护效力超10年","url":"https://stock-news.laohu8.com/highlight/detail?id=2430400804","media":"证券日报","top":-1,"share":"https://www.laohu8.com/m/news/2430400804?lang=zh_cn&edition=full","pubTime":"2024-04-25 20:21","pubTimestamp":1714047678,"startTime":"0","endTime":"0","summary":"近日，葛兰素史克（GSK）宣布，ZOSTER-049长期随访III期临床研究取得积极结果。这项研究对初次接种欣安立适（重组带状疱疹疫苗）的受试者进行了约11年的随访。最终数据显示，欣安立适在50岁及以上成人中的带状疱疹保护效力超过10年。据《证券日报》记者了解，ZOSTER-049是针对50岁及以上成人的两项III期临床试验（ZOE-50和ZOE-70）的扩展研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404253059598329.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430734334","title":"知名药企公布最新研究：重组带状疱疹疫苗能为50岁及以上成人提供超过10年高效保护","url":"https://stock-news.laohu8.com/highlight/detail?id=2430734334","media":"中国网财经","top":-1,"share":"https://www.laohu8.com/m/news/2430734334?lang=zh_cn&edition=full","pubTime":"2024-04-25 16:37","pubTimestamp":1714034229,"startTime":"0","endTime":"0","summary":"中国网财经4月25日讯针对带状疱疹的疫苗接种预防，全球知名生物医药企业带来了好消息。近日，葛兰素史克(GSK)宣布，ZOSTER-049长期随访III期临床研究取得积极结果，这项研究对初次接种欣安立适(重组带状疱疹疫苗)的受试者进行了约11年的随访。最终数据显示，欣安立适(重组带状疱疹疫苗)在50岁及以上成人中的带状疱疹保护效力超过10年。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202404253059367048.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404253059367048.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429687920","title":"葛兰素史克在英国市场涨约3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429687920","media":"新浪财经","top":-1,"share":"https://www.laohu8.com/m/news/2429687920?lang=zh_cn&edition=full","pubTime":"2024-04-22 22:48","pubTimestamp":1713797292,"startTime":"0","endTime":"0","summary":"格隆汇4月22日｜赛诺菲将支付1亿美元，以和解Zantac癌症官司。葛兰素史克(英国伦敦股价)涨幅扩大至2.7%。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：郭明煜","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2024-04-22/doc-inastpar2967060.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2428596259","title":"10年后防护效力达82%！GSK(GSK.US)带状疱疹疫苗长期随访结果公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2428596259","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428596259?lang=zh_cn&edition=full","pubTime":"2024-04-18 21:00","pubTimestamp":1713445201,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，GSK近日宣布其带状疱疹重组疫苗Shingrix，在长期随访3期临床试验ZOSTER-049中获得积极数据。最终数据显示，RZV对50岁以上成年人的带状疱疹防护效力超过十年。全球范围内，带状疱疹将影响多达1/3的人群。Shingrix是一种非活体、重组蛋白亚基疫苗，用于预防50岁及以上成年人的带状疱疹。它结合了抗原、糖蛋白E与佐剂系统AS01B，有助于克服与年龄相关的免疫反应衰减，这对于保护50岁及以上成年人免于带状疱疹发作至关重要。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1104887.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428935828","title":"SensorTower：美国市场2023年亚太汽车品牌贡献46%的汽车总销量 数字广告支出持续增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2428935828","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428935828?lang=zh_cn&edition=full","pubTime":"2024-04-17 10:37","pubTimestamp":1713321420,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，SensorTower发文称，美国是亚太汽车品牌的重要市场，Cox Automotive数据显示2023年亚太汽车品牌占据了该市场汽车总销量的46%。亚太汽车品牌在美国市场销量和广告支出保持领先地位亚太汽车品牌十分积极地投放数字广告，以保持领先的市场地位。Sensor Tower数据显示，近一年美国市场支出排名前10的汽车广告主中，亚太品牌超过7席。2023年Q2至2024年Q1，韩国汽车品牌Hyundai在美国数字广告支出环比增长42%，突破2亿美元，位居第一名。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1103711.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2427033336","title":"葛兰素史克与四川西部医药技术转移中心开展战略合作 提升我国呼吸慢病防治水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2427033336","media":"中国网财经","top":-1,"share":"https://www.laohu8.com/m/news/2427033336?lang=zh_cn&edition=full","pubTime":"2024-04-14 17:50","pubTimestamp":1713088200,"startTime":"0","endTime":"0","summary":"中国网财经4月14日讯 今日，葛兰素史克 与四川西部医药技术转移中心举行战略合作备忘录签约仪式，双方将就嗜酸粒细胞相关性呼吸疾病及共病诊疗能力提升项目开展战略合作。据四川西部医药技术转移中心理事长雷娟主任介绍，EOS相关疾病规范化诊疗中心项目启动后将在多个方面进行深入探索。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240414175502877a0a7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240414175502877a0a7b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425587474","title":"欧洲主要股指集体低开，阿斯麦公司跌超1%、GSK跌超2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2425587474","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2425587474?lang=zh_cn&edition=full","pubTime":"2024-04-05 15:11","pubTimestamp":1712301068,"startTime":"0","endTime":"0","summary":"更多消息，持续更新中","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/d0/24/94/-1-2-.png","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/d0/24/94/-1-2-.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3712068","is_publish_highlight":false,"gpt_icon":0},{"id":"2422861990","title":"国产九价HPV疫苗有望今年上市 市场格局或生变","url":"https://stock-news.laohu8.com/highlight/detail?id=2422861990","media":"新京报网","top":-1,"share":"https://www.laohu8.com/m/news/2422861990?lang=zh_cn&edition=full","pubTime":"2024-03-27 21:34","pubTimestamp":1711546440,"startTime":"0","endTime":"0","summary":"按照常规流程推算，公司九价HPV疫苗有望在今年获批。2018年4月28日，默沙东九价HPV疫苗也获批进入国内市场。很快，二价HPV疫苗迎来了国产入局者。进口九价HPV疫苗的接种次数也在减少。剩余市场空间取决于接种率默沙东九价HPV疫苗的关键专利将于2025年到期，在国产九价HPV疫苗上市之前，接种率成为决定剩余市场空间的关键。目前国内尚未将HPV疫苗纳入免疫规划，市场增长速度和空间规模势必会受到影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240327213600791d4b60&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240327213600791d4b60&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422238610","title":"药明生物2023年业绩稳健增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2422238610","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2422238610?lang=zh_cn&edition=full","pubTime":"2024-03-26 22:57","pubTimestamp":1711465020,"startTime":"0","endTime":"0","summary":"2023年业务亮点  尽管新冠疫情后面临严峻的宏观环境挑战，集团凭借独特的CRDMO商业模式和成功实施\"跟随并赢得分子\"战略，依然保持业务稳健增长。截至2023年12月31日，集团包括未完成服务订单和里程碑付款在内的未完成订单总额达206亿美元。临床后期和商业化生产收益增长至人民币77.3亿元，占2023年总收益的45.4%，延续集团临床后期和商业化生产业务加速增长势头。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4371111_ZH71111_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2421863703","title":"葛兰素史克(GSK.US)慢性咳嗽疗法在中国启动3期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2421863703","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2421863703?lang=zh_cn&edition=full","pubTime":"2024-03-22 15:50","pubTimestamp":1711093848,"startTime":"0","endTime":"0","summary":"2023年4月，葛兰素史克宣布已与Bellus Health达成并购协议，以总额约为20亿美元收购后者，从而囊获这款在研疗法。在一项2b期临床研究中，在接受治疗第28天时，camlipixant两种剂量水平使难治性慢性咳嗽患者经安慰剂调整的24小时咳嗽频率降低了34%，具有临床意义和统计学显著性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1090425.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2421270998","title":"葛兰素史克将为美国吸入器自付费用设定上限","url":"https://stock-news.laohu8.com/highlight/detail?id=2421270998","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2421270998?lang=zh_cn&edition=full","pubTime":"2024-03-21 04:50","pubTimestamp":1710967821,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社3月20日 - 英国制药巨头葛兰素史克公司（GSK.L）周三表示，它将把美国符合条件的所有吸入性哮喘和慢性肺病药物患者的自付费用上限定为每月35美元，此前它的两个竞争对手也采取了类似举措。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2420226652","title":"达3期临床试验OS主要终点！GSK(GSK.US)免疫组合疗法即将向FDA递交监管申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2420226652","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2420226652?lang=zh_cn&edition=full","pubTime":"2024-03-19 21:33","pubTimestamp":1710855229,"startTime":"0","endTime":"0","summary":"GSK将于2024年上半年向美国FDA递交监管申请，以扩大Jemperli的适应症至原发性晚期或复发性子宫内膜癌患者总人群。结果显示，Jemperli联合标准化疗，以及Jemperli联合标准化疗后续接Jemperli联合Zejula的安全性和耐受性特征与单个药物的已知安全性特征基本一致。据了解，Jemperli是一种能够与PD-1受体结合，并阻断其与配体PD-L1和PD-L2交互作用的抗体。在子宫内膜癌治疗方面，Jemperli已获美国FDA批准，作为在先前接受过含铂疗法后的错配修复缺陷型晚期或复发性子宫内膜癌的单药治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1088660.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2417768033","title":"葛兰素史克多发性骨髓瘤联合疗法试验中期分析获积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2417768033","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2417768033?lang=zh_cn&edition=full","pubTime":"2024-03-07 21:01","pubTimestamp":1709816494,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，葛兰素史克周四公布了一项评估复发或难治性多发性骨髓瘤联合疗法的试验中期分析取得积极结果。中期分析还观察到有利于Blenrep组合的积极总生存期趋势。此外，该联合疗法的安全性和耐受性与已知的单个药物的安全性大致一致。葛兰素史克早些时候公布了DREAMM-7试验的积极结果。截至发稿，葛兰素史克盘前涨2.63%，报43.74美元。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1083139.html","is_publish_highlight":true,"gpt_icon":1},{"id":"2417470722","title":"中外企业家热议政府工作报告：感受到国家对民营经济的支持，扩大对外开放的决心","url":"https://stock-news.laohu8.com/highlight/detail?id=2417470722","media":"澎湃新闻","top":-1,"share":"https://www.laohu8.com/m/news/2417470722?lang=zh_cn&edition=full","pubTime":"2024-03-06 07:07","pubTimestamp":1709680020,"startTime":"0","endTime":"0","summary":"　　3月5日，十四届全国人大二次会议在北京人民大会堂开幕，国务院总理李强作政府工作报告。　　值得一提的是，有外企高管向澎湃新闻记者表示，政府工作报告指出将“扩大高水平对外开放，促进互利共赢”，从中看到国家全面深化改革开放的决心和力度，为企业的在华发展提供了信心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-03-06/doc-inamisvx0397695.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-03-06/doc-inamisvx0397695.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2417417199","title":"美参议员抨击葛兰素史克涉嫌儿科哮喘药物价格欺诈，呼吁揭露“抢钱行为”并保障患儿权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2417417199","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2417417199?lang=zh_cn&edition=full","pubTime":"2024-03-05 04:09","pubTimestamp":1709582974,"startTime":"0","endTime":"0","summary":"沃伦指责葛兰素史克涉嫌在其儿科哮喘药物Flvent HFA及其授权仿制药的营销中进行价格欺诈，严重侵害了患儿及其家庭的权益。沃伦在声明中明确指出，葛兰素史克通过不断抬高儿科哮喘药物的价格，实施了一种“隐蔽而恶劣的价格欺诈”。沃伦敦促葛兰素史克立即公开授权仿制药的真实成本，并采取切实有效的措施来降低药物价格，确保所有患儿都能够获得必要的治疗。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/05040939728067.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2417841173","title":"葛兰素史克的新型艾滋病药物配方可支持更长的给药间隔时间","url":"https://stock-news.laohu8.com/highlight/detail?id=2417841173","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417841173?lang=zh_cn&edition=full","pubTime":"2024-03-05 02:45","pubTimestamp":1709577904,"startTime":"0","endTime":"0","summary":"葛兰素史克旗下专注于艾滋病防治的 ViiV Healthcare 公司在逆转录病毒和机会性感染大会上公布了超长效 cabotegravir 的数据，该公司计划在今年晚些时候进行大规模临床试验。该药物是葛兰素史克预计在未来几年发布的十几种重要产品之一。在一系列专利即将到期、诉讼和现有畅销药物收入下降的情况下，葛兰素史克已将其艾滋病治疗重点转向长效治疗和预防疗法。葛兰素史克公司还计划在2026年推出首款预防艾滋病的超长效药物，随后在2027年推出超长效艾滋病治疗药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2415510962","title":"葛兰素史克(GSK.US)在加州解决第二起Zantac癌症诉讼","url":"https://stock-news.laohu8.com/highlight/detail?id=2415510962","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2415510962?lang=zh_cn&edition=full","pubTime":"2024-02-29 20:00","pubTimestamp":1709208000,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，英国制药巨头葛兰素史克(GSK.US)将在加州就其畅销的胃灼热药物Zantac在美国提起的诉讼达成和解，这是本月第二起此类诉讼。该公司表示，已与名为Boyd/Steenvoord的原告达成保密和解，解决了这起原定于4月2日在加利福尼亚州法院开庭审理的案件。对葛兰素史克和其他公司提起诉讼的Zantac前使用者声称，该药的活性成分雷尼替丁在某些条件下会降解，变成一种名为NDMA的潜在致癌物。这些公司否认了这些说法。葛兰素史克表示，和解“反映出公司希望避免因旷日持久的诉讼而分散注意力”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1079232.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2414589887","title":"GSK(GSK.US)潜在“first-in-class”小分子疗法达到关键性3期临床试验终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2414589887","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2414589887?lang=zh_cn&edition=full","pubTime":"2024-02-27 08:34","pubTimestamp":1708994050,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，GSK宣布，潜在“first-in-class”口服抗生素gepotidacin在针对青少年和成人非并发性尿生殖道淋病的关键性3期临床试验EAGLE-1中取得积极结果。该试验达到了其主要疗效终点，与静脉注射头孢曲松加口服阿奇霉素的常用联合治疗方案相比，gepotidacin显示出非劣效性。淋病是由一种名为淋球菌的细菌引起的性传播感染。GSK还在开发gepotidacin用于治疗非并发性尿路感染。EAGLE-2和EAGLE-3的两项3期临床试验的积极数据已在《柳叶刀》杂志上发表。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1077187.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gsk.com","stockEarnings":[{"period":"1week","weight":0.0342},{"period":"1month","weight":-0.0437},{"period":"3month","weight":0.0522},{"period":"6month","weight":0.1895},{"period":"1year","weight":0.1416},{"period":"ytd","weight":0.1093}],"compareEarnings":[{"period":"1week","weight":0.0265},{"period":"1month","weight":-0.0285},{"period":"3month","weight":0.0428},{"period":"6month","weight":0.2376},{"period":"1year","weight":0.2324},{"period":"ytd","weight":0.0693}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"GSK Plc于1999年12月6日在英国成立的公众服务有限公司，是一个世界领先的研究型制药和保健公司，由 Glaxo Wellcome plc和SmithKline Beecham plc合并而成。公司致力于开发较现有治疗方案明显改善的新产品，为病人和政府、保险公司或其他第三方提供帮助。","yearOnYearQuotes":[{"month":1,"riseRate":0.568182,"avgChangeRate":0.012276},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.003512},{"month":3,"riseRate":0.613636,"avgChangeRate":0.0208},{"month":4,"riseRate":0.666667,"avgChangeRate":0.03255},{"month":5,"riseRate":0.386364,"avgChangeRate":-0.010964},{"month":6,"riseRate":0.613636,"avgChangeRate":0.014726},{"month":7,"riseRate":0.545455,"avgChangeRate":0.004705},{"month":8,"riseRate":0.568182,"avgChangeRate":0.001515},{"month":9,"riseRate":0.522727,"avgChangeRate":0.005813},{"month":10,"riseRate":0.522727,"avgChangeRate":0.013998},{"month":11,"riseRate":0.477273,"avgChangeRate":0.011509},{"month":12,"riseRate":0.613636,"avgChangeRate":0.014479}],"exchange":"NYSE","name":"葛兰素史克","nameEN":"GlaxoSmithKline PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供葛兰素史克(GSK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"葛兰素史克,GSK,葛兰素史克股票,葛兰素史克股票老虎,葛兰素史克股票老虎国际,葛兰素史克行情,葛兰素史克股票行情,葛兰素史克股价,葛兰素史克股市,葛兰素史克股票价格,葛兰素史克股票交易,葛兰素史克股票购买,葛兰素史克股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供葛兰素史克(GSK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}